BioSpace News Archive

Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies, provided financial results for its third fiscal quarter ended December 31, 2019.

BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev, introduces a novel method developed by researchers at Ben-Gurion University for screening and detecting new antibiotics.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced upcoming presentations from its neurometabolic franchise at the 16th Annual WORLD Symposium on February 10-13 in Orlando, FL

Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, announced today that Pete Salzmann, Chief Executive Officer, will provide a corporate overview at the SVB Leerink 9th Annual Global Healthcare Conference, taking place February 25-27 in New York City.

vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D).

Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel cell therapy products, issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay.

Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company,” a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a $5 million convertible equity financing with Novartis Pharma

Cepheid today announced that in response to the rapid outbreak of a new coronavirus strain, the Company is developing an automated molecular test for the qualitative detection of 2019-nCoV.

CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced the appointment of Roger J. Pomerantz, M.D., F.A.C.P. to its Board of Directors as Chairman, effective immediately. Dr. Pomerantz is currently the President, Chief Executive Officer and Chairman of the Board of Directors of ContraFect.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will feature 11 presentations, including 10 posters, and one oral presentation highlighting its ongoing studies and commitment to rare lysosomal storage disorders at the 16th annual WORLDSymposium™ 2020 in Orlando, Florida, February 10-13.